Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevabertinib effect on metformin PK in healthy participants
NCT07753252Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sevabertinib in non-small cell lung cancer (NSCLC), sponsored by Bayer. Primary endpoints: Area Under the Curve of metformin, Area Under the Curve from time 0 to tlast of metformin and 1 more. Started Aug 2026; status: completed.
02
Drugs
sevabertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07753252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753252.